Highlights and Quick Summary
- EBIT Margin for the quarter ending September 30, 2022 was -95.53% (a -10.02% decrease compared to previous quarter)
- Year-over-year quarterly EBIT Margin decreased by -40.91%
- Annual EBIT Margin for 2021 was -75.11% (a 49.21% increase from previous year)
- Annual EBIT Margin for 2020 was -50.34% (a -53.78% decrease from previous year)
- Annual EBIT Margin for 2019 was -108.92% (a -38.39% decrease from previous year)
- Twelve month EBIT Margin ending September 30, 2022 was -135.02% (a -17.03% decrease compared to previous quarter)
- Twelve month trailing EBIT Margin increased by 79.76% year-over-year
Trailing EBIT Margin for the last four month:
| 30 Sep '22 | 30 Jun '22 | 31 Mar '22 | 31 Dec '21 |
|---|---|---|---|
| -135.02% | -162.73% | -154.77% | -75.11% |
Visit stockrow.com/BDSX
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical EBIT Margin of Biodesix, Inc.
Most recent EBIT Marginof BDSX including historical data for past 10 years.Interactive Chart of EBIT Margin of Biodesix, Inc.
Biodesix, Inc. EBIT Margin for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | -95.53% | -106.17% | -220.85% | – |
| 2021 | -161.67% | -200.44% | -89.08% | -19.34% | -75.11% |
| 2020 | -9.82% | -67.88% | -132.55% | -165.27% | -50.34% |
| 2019 | – | – | 0.0% | -229.02% | -108.92% |
| 2018 | – | – | – | – | -176.79% |
Business Profile of Biodesix, Inc.
Sector: Healthcare
Industry: Diagnostics & Research